Unitaid announced a US$15 million funding expansion to accelerate the rollout of long-acting injectable lenacapavir for HIV prevention, building on a broader US$110 million investment, according to a news release issued by the organization. The fresh funding aims to widen community access across Africa, Latin America, Eastern Europe, and Southeast Asia as health programs navigate funding cuts, and it prepares healthcare systems for upcoming innovations including once-monthly oral pills and one-year protection formulations.
Global South Partnerships and Project Implementation
The funding rollout relies on three complementary Global South-led projects designed to dismantle practical barriers, according to Unitaid. Wits RHI oversees implementation in partnership with the Clinton Health Access Initiative, the International Treatment Preparedness Coalition, and the University Teaching Hospital/Ministry of Health Zambia. These organizations work together to secure community leadership, speed up administrative introductions, and stabilize supply ecosystems.
“The investment will also help prepare health systems for other anticipated innovations in HIV prevention including a once-monthly oral pill and a new formulation of lenacapavir that provides one year of protection.” — Unitaid News Release
Preparing Health Systems for Next-Generation Prevention
Looking Beyond Lenacapavir: Monthly Pills and Yearly Depots
Did you know?
Frequently Asked Questions
What is lenacapavir?
Lenacapavir is a breakthrough long-acting medicine used for preventing HIV, designed to provide extended protection compared to traditional daily oral medications.
Which regions are receiving the expanded Unitaid support?
The expansion targets countries across Africa, Latin America, Eastern Europe, and Southeast Asia preparing to roll out lenacapavir amidst funding constraints in global health.
Who is implementing the new Unitaid-funded projects?
The projects are led by the Global South, featuring Wits RHI, the Clinton Health Access Initiative, the International Treatment Preparedness Coalition, and the University Teaching Hospital/Ministry of Health Zambia.
Are you tracking developments in long-acting HIV prevention tools, or do you work within public health infrastructure? Share your perspective in the comments below, or subscribe to our newsletter for regular updates on global health financing and therapeutic rollouts.
Keep reading